Agaricus blazei Murill Extract Abrogates CCl₄-induced Liver Injury in Rats

MING-FANG WU¹, YU-MING HSU¹, MING-CHU TANG¹, HSUEH-CHIN CHEN¹, JING-GUNG CHUNG²,³, HSU-FENG LU⁴, JING-PIN LIN⁵, NOU-YING TANG⁵, CHUN YEH⁶ and MING-YANG YEH⁷

¹Animal Medicine Center, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.; ²Department of Biological Science and Technology, ³School of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C.; ⁴Division of Gastroenterology, Department of Internal Medicine, ⁵Office of Director, Cheng-Hsin General Hospital, Taipei, Taiwan, R.O.C.

Abstract. Agaricus blazei Murill (ABM) is traditionally used as a health food source in Brazil for the prevention of cancer, allergy, diabetes, hyperlipidemia, etc. Many studies have shown that ABM possesses immune-enhancing and anti-tumor effects. However, little is known about its protective effects on liver function. We employed carbon tetrachloride (CCl₄) to induce hepatic fibrosis in a rat model to examine the protective effects of ABM on the liver in this study. The experiments included non-treatment control, CCl₄-only control, and treatment with 200 mg and 2,000 mg of ABM extracts (per kilogram rat weight). All groups other than the non-treatment control were treated with intraperitoneal injections of CCl₄ twice a week. Experimental and control rats were tube-fed with experimental ABM extracts or double-distilled water, respectively, on the remaining days each week. The whole experimental protocol lasted 8 weeks; blood and liver samples were collected for biochemical and tissue histochemical analysis. Plasma alanine aminotransferase and aspartate aminotransferase, and the activities of the antioxidative enzymes glutathione peroxidase, superoxide dismutase and catalase in the liver were measured. We found that high-dose ABM treatment reduced hepatic necrosis and fibrosis caused by CCl₄ in comparison with the CCl₄ control group. ALT and AST activities in the sera collected from ABM-treated rats were lower than those in the CCl₄ control rats. These results suggested that ABM extract was capable of either enhancing liver recovering from CCl₄ damage or attenuating CCl₄ toxicity. Results of antioxidative enzyme activity analysis showed no apparent differences among ABM-treated groups and CCl₄ control groups, indicating that removal of free radicals does not explain the protective/recovery effects observed in this study.

Hepatic fibrosis results from chronic damage to the liver in conjunction with the progressive accumulation of fibrillar extracellular matrix protein (1-3). The main causes of hepatic fibrosis in humans include infection by hepatitis B and C, alcohol abuse and non-alcohol steatohepatitis; and experimentally, liver cirrhosis can be induced by carbon tetrachloride (CCl₄) (4-5). Hepatic fibrosis is triggered by specific extracellular interactions among Kuffer cells which are activated by membrane components from damaged hepatocytes and infiltrating inflammatory cells. The activated Kuffer cells release pro-fibrotic factor such as transforming growth factor B, reactive oxygen species (ROS), and other effecting factors (5-6). These pro-fibrotic factors play key roles in hepatic fibrosis (2).

Many studies have shown that ROS, including oxygen free radicals, are causative factors in the etiology of degenerative diseases, including hepatopathies (7-8). For example, CCl₄-mediated hepatic necrosis involves bioactivation by the microsomal P450-dependent monooxygenase system, resulting in the formation of trichloromethyl free radicals and ROS that initiate lipid peroxidation and protein oxidation (9). ROS can also modify and damage proteins, carbohydrates, and DNA both in vitro and in vivo (10).

The Basidiomycete fungus Agaricus blazei Murill (ABM) is traditionally used as a health food source in Brazil for the prevention of cancer, allergy, diabetes, hyperlipidemia,
arteriosclerosis, and chronic hepatitis, as well as an anti-inflammatory, anti-bacterial and anti-viral (11-15). ABM contains a variety of polysaccharides and is considered a health food in many countries. ABM was reported to be a source of antitumor and immune-enhancing compounds (13). To our knowledge, there are no published data documenting the antioxidative and hepatoprotective effects of ABM.

The purpose of this research was to examine and compare biological activities of an ABM extract in rats with chronic CCl4-induced liver injury, to evaluate the therapeutic effects of ABM, to probe potential mechanisms and to determine whether therapeutic effect occurred in a dose-dependent manner or not.

Materials and Methods

Reagents. Carbon tetrachloride (CCl4), olive oil and other reagents were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA). Diagnostic kits for assaying alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were purchased from Arkray, Inc. (Kyoto, Japan). Other assay kits were obtained from Cayman Chemical (Ann Arbor, MI, USA).

Animals. Male Wistar rats, specific pathogen-free, 6 weeks old and weighing 250-300 g, obtained from the Animal Medicine Center, College of Medicine, National Taiwan University were used for the chronic CCl4-induced liver injury model in all experiments. The animals were maintained in a standard laboratory under a 12-h light/dark cycle in a temperature (20±2°C), humidity (75±15%), and filtered laminar air flow controlled room in the animal facility of the Animal Medicine Center, College of Medicine, National Taiwan University, Taipei, Taiwan. Rats were raised and cared for, given autoclaved water and fed ad libitum with laboratory pellet chow following the guidelines set up the National Science Council of the Republic of China. Experiments were performed according to regulations and guidelines for animal experiments in Taiwan, which are in agreement with the Helsinki declaration.

Preparation of ABM extracts. ABM was obtained from S. Canaan Biotechnology Development Co. (Taipei, Taiwan, ROC). Air-dried ABM samples were ground and then mixed with double-distilled water at 100˚C for 10 min, and then cooled to room temperature. ABM was stored at 4˚C in dark bottles and kept sterile until instilled intragastrically in the rats.

Experimental design. Forty rats were divided into four groups (each group consisted of 10 rats): (I) As a normal control, rats were fed with regular diet and double-distilled water. (II) Rats were treated with 40% CCl4/olive oil (1 ml/kg body weight per day, i.p., twice per week) for 8 weeks to induce chronic chemical liver injury as a negative control. (III) Rats were treated with 40% CCl4/olive oil (1 ml/kg body weight per day, i.p., twice per week) and with a low dose of 200 mg/kg (p.o., 4 days per week) ABM extract treatment for 8 weeks. (IV) Rats were treated with 40% CCl4/olive oil (1 ml/kg body weight per day, i.p., twice per week) and with a high dose of 2000 mg/kg (p.o., 4 days per week) ABM extract treatment for 8 weeks.

Table I. Comparison of CCl4-induced liver histopathological alterations. There were 1, 2 and 2 rats dead in the CCl4 control, 200 mg/kg and 2000 mg/kg ABM groups, respectively.

<table>
<thead>
<tr>
<th>Group</th>
<th>Level of cavitation</th>
<th>Level of fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>I</td>
</tr>
<tr>
<td>Negative control</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>CCl4 control</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>200 mg/kg ABM</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>2000 mg/kg ABM</td>
<td>8</td>
<td>0</td>
</tr>
</tbody>
</table>

Figure 1. Effects of the ABM extract on plasma ALT and AST in CCl4-intoxicated rats. CCl4-intoxicated rats were treated with vehicle solution (double-distilled water) or two different doses of ABM extract (200 and 2000 mg/kg) for 8 weeks. Animals were treated with double-distilled water without CCl4 as the negative control group. Plasma ALT and AST levels were determined as described in the Materials and Methods. Results are presented the means±SEM (n=10).
Blood samples (0.2 ml with 10 U/ml heparin) were collected in orbital bleeding at the end of the first, third, sixth, and eighth weeks. At the end of the experiments, blood and livers were collected immediately after the animals were sacrificed at week 8 under anesthesia by CO₂. Livers were weighed and utilized for the following biochemical and histology analyses.

**Measurement of plasma transaminase activities.** Plasma samples were prepared at the end of the eighth weeks and analyzed using ALT and AST diagnostic kits, following the manufacturer’s protocols. ALT and AST enzyme activities were measured by the Hitachi 717 (Tokyo, Japan) instrument and Boehringer Mannheim (Mannheim, Germany) reagent. Analytical procedures were performed according to the manufacturer’s instructions (16).

**Glutathione peroxidase (GSHPx) assay.** Liver was homogenized with GSHPx cold buffer (50 mM Tris-HCl containing 5 mM EDTA and 1 mM dithiothreitol (DTT), pH 7.5). GSHPx activity was measured by a GSHPx assay kit (17). The reaction was initiated by the mixing glutathione, glutathione reductase, NADPH with cumene (isopropylbenzene) hydroperoxide, and then detecting conversion of NADPH to NADP with a spectrophotometer at 340 nm for 5 min. The specific activity was measured as nanomoles of NADPH oxidized to NADP per minute per milligram protein.

**Catalase assays.** Liver tissues were homogenized in a cold buffer (50 mM potassium phosphate and 1 mM EDTA, pH 7.0). Supernatant was collected and hydrogen peroxide added as exogenous substrate. The activity of catalase was measured using a catalase assay kit (Cayman Chemical Company) as reported previously (18). Change in the absorbance was monitored at 540 nm according to the manufacturer’s protocol.

**Histological assay.** Rats were sacrificed at the end of the eighth week, and the livers were immediately removed. Liver slices were made from a part of the left and central lobes, and immediately fixed in 10% buffered formalin phosphate solution, embedded in paraffin, and stained with hematoxylin and eosin (H&E) or Masson’s trichrome (MT). Liver pathology was rated on four levels based on Ruwart et al. (19): None (I), no detectable pathological

**Figure 2. Histopathological analysis of rat liver sections using H&E staining.** A: Section from a negative control rat liver. B: The liver section obtained from CCl₄-intoxicated rats shows a variety of cavitations and necrosis in hepatocytes. C: Liver tissue section prepared from the 2,000 mg/kg ABM-treated group shows less cavitation and necrosis compared to B. D: Liver tissue section prepared from the 200 mg/kg ABM-treated group shows less cavitation and necrosis.
alternation; focal (II), focal and local alternation; multifocal (III), multiple focal alterations; diffuse (IV) represents broad diffuse alteration. Stage assessment of hepatic fibrosis was rated: (I), fibrosis only occurring in the portal area; (II), portal area fibrosis extends to the hepatic lobule but focal fibrosis does not link these; (III), the portal fibrosis extends into the hepatic lobule, a clear pseudo-lobule is formed and bile duct hyperplasia occurs.

Statistical analysis. The experimental results are expressed as the means±SEM and are accompanied by the number of observations. Data were assessed by analysis of variance (ANOVA) and Student’s t-test. If the analysis indicated significant differences among the group means, then each group was compared by the Newman-Keuls method.

Results

Plasma transaminases. Blood was collected at the indicated times for ALT and AST determination after CCl4 administration. Both plasma ALT and AST levels were markedly increased (Figure 1A and 1B) after CCl4 treatment as compared to the normal group (double-distilled water treatment). On the other hand, ABM extract (200 mg/kg and 2,000 mg/kg) significantly reduced ALT and AST levels at the eighth week as compared with those of the group treated with CCl4 alone (Figure 1).

Histopathological assessment. Liver tissue sections were stained with either H&E (Figure 2) or MT (Figure 3). Negative control tissue sections exhibited no apparent pathological alterations (Figure 2A and Figure 3A). No cavitations, necrosis or fibrosis were found in control sections. In contrast, sections from CCl4-only treated rats displayed apparent cavitations in broad areas (Figure 2B). However, the broad cavitations in liver were attenuated in rats treated with ABM during the experimental periods. ABM administration resulted in less cavitation in the liver, shown in Figure 2C and Figure 2D. Interestingly, the cavitation level in the 200 mg/kg ABM group was lower than that in the 2,000 mg/kg ABM group. Liver sections prepared
from ABM groups (Figure 3C and 3D) displayed less fibrosis as compared to the CCl₄ control group (Figure 3B). The reduction in the 200 mg/kg ABM group (Figure 3D) was more obvious in comparison to that of the 2,000 mg/kg ABM group (Figure 3C). We also examined the distribution of fibrosis in different liver regions (from central vein region to hepatic portal veins) (Table I). Both dosages of ABM reduced apparent liver injury caused by CCl₄, compared to the CCl₄ control.

Assessment of antioxidant enzyme activities. To investigate the role of antioxidant enzyme activities in the liver during CCl₄ injury, we analyzed GSHPx, catalase and SOD. CCl₄ toxicity resulted in lower GSHPx and catalase activities (Figure 4A and 4B), but slightly increased SOD activity (Figure 4C). GSHPx activity in both ABM groups was not significantly different from that of the CCl₄ control (Figure 4A). ABM administrations did not significantly alter catalase activity caused by CCl₄ (Figure 4B). Furthermore, SOD activities were not significantly different in the CCl₄ control group and the two ABM groups (Figure 4C). These results show that the effects of ABM observed in Figures 2 and 3 cannot be explained by antioxidant pathways.

Discussion

ABM has been employed as an alternative antitumor therapy for years. The biological activities and mechanisms of ABM have been reported by several groups (11-15). Mostly, previous research has focused on the immune and anti-inflammatory activities of ABM (12). Our study presents original research focusing on protection of the liver and counteraction against hepatic fibrosis.

Carbon tetrachloride has been widely used to induce liver injury in animal models (8). CCl₄ is metabolized to CCl₃ by CYP450 in hepatocytes. Subsequently, CCl₃ reacts with oxygen to form CCl₃OO. Both CCl₃ and CCl₃OO trigger super-oxidative chain reactions in lipid molecules (9). Further reactions with phospholipids and polyunsaturated fatty acids can affect the permeability of the cell membrane, the mitochondria, and the reticular membranes (2). Consequently, elevation of cytosol calcium leads to cell damage (7). In our CCl₄-induced chronic liver injury model, we observed that the livers in ABM extract-treated rats displayed less injury in the histochemical analyses compared to those in the CCl₄-only treated group. Hepatic fibrosis, necrosis, and cavitations caused by CCl₄ were attenuated by ABM extract administration. These results indicate that ABM extracts have recovery/reparative effects on CCl₄-induced liver injury.

ABM extracts were found to reduce the activities of plasma ALT and AST which were elevated by CCl₄. Both dosages of ABM abrogated the CCl₄ effects on plasma ALT and AST in an apparent dose-dependent manner. This suggests that ABM extract plays a role in ALT/AST release mechanism. Analysis of anti-oxidant enzymes showed that ABM extracts had no significant effect on the activities of GSHPx, catalase and SOD under CCl₄ treatment. These results indicate that the recovery/reparative effects of ABM extracts shown by the histopathological observations are not through antioxidant mechanism. Removal of free radicals is not likely to contribute to the effects of ABM.

Our results provide first evidence that ABM extract has recovery/reparative effect on CCl₄-induced liver injury.
ALT/AST analyses suggest that active components in the ABM extract act directly or indirectly on the hepatic cell membrane. Two concentrations of ABM were examined in this report. However, the optimal concentration of ABM extract in the CCl_4 experimental model requires further study.

Acknowledgements

This study was supported by grant CMU97-276 from China Medical University and Asia University, Taichung, Taiwan, R.O.C.

Reference


13 Ellertsen LK and Hetland G: An extract of the medicinal mushroom Agaricus blazei Murill can protect against allergy. Clin Mol Allergy 7(6), 2009.


Received July 12, 2010
Revised September 2, 2010
Accepted September 2, 2010